NEW YORK (GenomeWeb News) – Autoimmune molecular diagnostics firm Ignyta today said it is working with Leiden University Medical Center to evaluate epigenetic signatures of patients with early synovitis and rheumatoid arthritis.
Financial and other terms of the collaboration were not disclosed.
"With the signing of this collaboration with LUMC, Ignyta now has a global reach to study patients with undifferentiated arthritis and rheumatoid arthritis, taking us another step closer to achieving our goal of developing a diagnostic assay for patients with early RA," Jonathan Lim, co-founder, chairman, and CEO of Ignyta, said in a statement.
Based in San Diego, Ignyta was founded in 2011 with technology licensed from the University of California, San Diego. The company was formerly called NexDx. Last month, it announced it raised $5.5 million in an expanded Series B financing round.